Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 1,756.00
+19.00 (1.09%)
Sep 14, 2026, 3:30 PM JST
Fuji Pharma Ratios and Metrics
Market cap in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 45,866 | 37,703 | 30,950 | 28,337 | 25,121 | 28,416 | |
Market Cap Growth | 18.06% | 21.82% | 9.22% | 12.80% | -11.60% | -26.98% |
Enterprise Value | 64,812 | 62,378 | 57,137 | 54,046 | 45,919 | 37,050 |
Last Close Price | 1756.00 | 1531.92 | 1223.50 | 1087.99 | 934.46 | 1021.43 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
PE Ratio | 14.71 | 12.57 | 5.04 | 8.25 | 9.32 | 11.68 |
Forward PE | 9.90 | 10.31 | 7.24 | 8.29 | 8.47 | 12.03 |
PS Ratio | 0.76 | 0.73 | 0.67 | 0.69 | 0.71 | 0.84 |
PB Ratio | 0.88 | 0.80 | 0.68 | 0.69 | 0.70 | 0.87 |
P/TBV Ratio | 1.20 | 1.14 | 0.94 | 0.92 | 0.99 | 0.94 |
P/FCF Ratio | 8.33 | 9.87 | 22.54 | - | - | 12.89 |
P/OCF Ratio | 5.93 | 6.50 | 7.46 | 14.78 | - | 4.74 |
PEG Ratio | - | 1.12 | 1.12 | 1.12 | 1.12 | 1.12 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
EV/Sales Ratio | 1.08 | 1.21 | 1.24 | 1.32 | 1.30 | 1.09 |
EV/EBITDA Ratio | 5.79 | 6.97 | 7.56 | 7.85 | 7.04 | 6.79 |
EV/EBIT Ratio | 9.23 | 12.50 | 14.72 | 14.01 | 12.15 | 11.06 |
EV/FCF Ratio | 11.77 | 16.33 | 41.61 | - | - | 16.81 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Debt / Equity Ratio | 0.56 | 0.66 | 0.64 | 0.70 | 0.69 | 0.57 |
Debt / EBITDA Ratio | 2.58 | 3.45 | 3.87 | 4.21 | 3.77 | 3.42 |
Debt / FCF Ratio | - | 8.10 | 21.31 | - | - | 8.47 |
Net Debt / Equity Ratio | 0.37 | 0.51 | 0.54 | 0.65 | 0.59 | 0.26 |
Net Debt / EBITDA Ratio | 1.69 | 2.65 | 3.26 | 3.87 | 3.22 | 1.55 |
Net Debt / FCF Ratio | - | 6.20 | 17.97 | -18.88 | -3.65 | 3.84 |
Asset Turnover | 0.63 | 0.56 | 0.53 | 0.51 | 0.51 | 0.54 |
Inventory Turnover | 1.54 | 1.58 | 1.51 | 1.39 | 1.50 | 1.70 |
Quick Ratio | 0.91 | 0.82 | 0.66 | 0.63 | 0.68 | 1.10 |
Current Ratio | 1.66 | 1.55 | 1.19 | 1.31 | 1.45 | 1.73 |
Return on Equity (ROE) | 6.14% | 6.49% | 14.17% | 8.92% | 7.87% | 6.70% |
Return on Assets (ROA) | 4.57% | 3.40% | 2.77% | 3.00% | 3.38% | 3.32% |
Return on Invested Capital (ROIC) | 8.73% | 5.32% | 4.18% | 4.84% | 5.59% | 5.95% |
Return on Capital Employed (ROCE) | 10.70% | 8.00% | 7.20% | 6.90% | 7.30% | 7.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Earnings Yield | 6.52% | 7.96% | 19.86% | 12.12% | 10.73% | 8.56% |
FCF Yield | 12.01% | 10.13% | 4.44% | -4.98% | -22.91% | 7.76% |
Dividend Yield | 2.78% | 2.97% | 3.47% | 3.40% | 3.74% | 2.84% |
Payout Ratio | - | 34.53% | 15.82% | 26.17% | 27.04% | 33.18% |
Buyback Yield / Dilution | -2.77% | -0.38% | -0.04% | -0.03% | 9.58% | 13.77% |
Total Shareholder Return | 0.01% | 2.59% | 3.44% | 3.37% | 13.32% | 16.61% |